Ivy Gourd for Blood Sugar
Ivy gourd (Coccinia grandis) is a climbing plant of the gourd family. Its fruit and leaves are eaten as a vegetable in South Asia, and the plant has a long record of use in traditional medicine for diabetes. Two randomized, placebo-controlled trials in people with newly diagnosed type 2 diabetes, one of 60 people and one of 158, found lower blood glucose and lower hemoglobin A1C (HbA1c) after about three months of an ivy gourd preparation. HbA1c is a blood test that reflects average blood glucose over roughly the previous three months.
Evidence base: two randomized trials against placebo, one single-meal study in healthy volunteers, and animal and laboratory work. Published reviews describe the human evidence for ivy gourd as conflicting or still insufficient, and none of the studies this page draws on tested ivy gourd against, or together with, a diabetes medicine.
Table of Contents
What the Plant Is and How It Has Been Used
One Plant, Three Botanical Names
Recent papers call the plant Coccinia grandis. Other papers call the same plant Coccinia indica or Coccinia cordifolia. A 2008 trial report states that those two names are synonyms (PMID 18000183), and both a 2017 paper that uses Coccinia indica and a 2025 review that uses Coccinia grandis give the common name ivy gourd (PMID 28479735, PMID 41504092). A study found under any of the three names is a study of the same plant. This page uses “ivy gourd” throughout. In Sri Lanka the plant is known locally as Ken or Kovakka (PMID 21822423).
Ivy gourd is not ivy leaf. Ivy leaf comes from common ivy (Hedera helix), an unrelated plant, and nothing on this page applies to it.
A Vegetable and a Traditional Remedy
A 2025 review describes ivy gourd as popularly eaten in South Asia both as food and for therapeutic purposes, and lists diabetes among many conditions it has traditionally been used for, alongside high blood pressure, ulcers, diarrhea, jaundice, fever, skin eruptions and others (PMID 41504092). That list records traditional use. It is not a list of proven effects.
The 2008 trial report describes the plant as a herb that grows abundantly in India and has been used in the traditional treatment of diabetes (PMID 18000183). A field survey in the Mymensingh district of Bangladesh found that traditional practitioners of one community there used twelve medicinal plants for diabetes, and ivy gourd was one of the twelve (PMID 23983370). Two reviews of botanical supplements list ivy gourd among the plants most often used or promoted to help manage blood glucose (PMID 28729836, PMID 18537692).
Which Part of the Plant Each Study Tested
Studies of ivy gourd did not all test the same part of the plant, and a result for one part does not automatically hold for another.
- Leaves: the single-meal study in healthy volunteers used fresh leaves in a meal (PMID 21822423); a laboratory enzyme study and two rat studies used leaf extracts (PMID 39045303, PMID 39079440, PMID 33887972).
- Fruit: one rat study used an extract of the fruit (PMID 28479735).
- Stems: one laboratory study isolated a compound from the stems (PMID 38718496).
- Part not stated: the abstract of the 2008 trial says only “alcoholic extract of the herb” (PMID 18000183). The abstract of the 2021 trial calls its product a newly developed herbal formulation and does not name the plant part, though it introduces the trial as following earlier animal and laboratory work on a water extract of the leaves (PMID 33352495).
Active Compounds and How They Act
What Chemists Have Found in the Plant
The 2025 review reports that researchers have identified compounds from many chemical classes in ivy gourd: alkaloids, flavonoids, coumarins, esters, ethers, fatty acids, fatty alcohols, terpenoids and phenolic compounds. The same review states that the specific compounds responsible for the plant’s biological effects, and the way they act, are yet to be fully identified (PMID 41504092). In plain words: nobody has yet shown which substance in ivy gourd, if any, lowers blood sugar in people.
Individual studies have isolated or counted compounds from different parts of the plant:
- Fruit: three compounds of a class called cucurbitane-type triterpenoids, named coccinoside A, B and C, were isolated from a fruit extract that lowered blood glucose in diabetic rats (PMID 28479735).
- Stems: a compound identified as 2,4-ditertiary butyl phenol was isolated from the stems and tested in the laboratory against a starch-digesting enzyme (PMID 38718496).
- Leaves: sixteen compounds were identified in a leaf extract, which also measured high in phenols, flavonoids and tannins (PMID 39045303).
The Proposed Action: Slowing the Breakdown of Starch
Starch in rice, bread or potatoes cannot enter the blood as it is. Two digestive enzymes, alpha-amylase and alpha-glucosidase, first cut it into glucose. A substance that blocks these enzymes slows that cutting, so glucose reaches the blood more slowly after a meal. One laboratory paper describes blocking pancreatic alpha-amylase as a strategy to lower the rise in blood sugar after meals through control of starch breakdown (PMID 21251279). Acarbose, a prescription medicine that works this way, is the usual comparison in these laboratory tests.
In a laboratory enzyme test, an ivy gourd leaf extract blocked both enzymes, and the authors reported that the blocking was stronger than that of acarbose (PMID 39045303). This is a test-tube finding. It shows what the extract does to an enzyme in a dish, not what a leaf does in a human gut. Other laboratory screens, described below, did not find ivy gourd among their strongest enzyme blockers.
A second proposed action comes from one rat study, in which a two-plant extract containing ivy gourd leaf raised the amount of insulin seen in the pancreas (PMID 39079440). A general review of anti-diabetic herbs states that, for the majority of such herbs, the proposed mechanisms involve the cell’s insulin signalling pathways, the movement of the glucose transporter type 4 (GLUT-4) to the cell surface, or activation of a receptor called peroxisome proliferator-activated receptor gamma, and that several flavonoids slow glucose absorption by blocking alpha-amylase and alpha-glucosidase in the intestine (PMID 28729836). That statement is about herbs as a group; the review’s abstract does not say which of these applies to ivy gourd.
What Human Trials Found
Three human studies of ivy gourd are described here. Two are randomized controlled trials in people with type 2 diabetes: participants were assigned by chance to ivy gourd or to a look-alike placebo, and neither they nor the researchers knew who received which (“double-blind”). The third is a single-meal study in healthy volunteers. All three compared ivy gourd with a placebo. None compared it with a diabetes medicine, and none tested it as a replacement for one.
| Study | People | What was given | Compared with | Length | Main result |
|---|---|---|---|---|---|
| India, 2008. Randomized, double-blind trial | 60 adults aged 35–60 with newly detected type 2 diabetes managed by diet and lifestyle only | 1 g of an alcoholic extract | Placebo | 90 days | Fasting glucose down 16% and after-meal glucose down 18% at day 90; HbA1c lower than with placebo; blood lipids unchanged |
| Sri Lanka, 2021. Randomized, double-blind trial | 158 people with newly diagnosed type 2 diabetes (145 completed) | 500 mg of a herbal preparation once daily | Placebo | Three months | HbA1c, fasting glucose and five other measures changed significantly more than with placebo; the remaining outcomes did not differ |
| Sri Lanka, 2011. Double-blind single-meal study | Healthy volunteers, 61 in each group | One breakfast containing 20 g of leaves | Placebo meal | One meal, with blood tests for two hours | Blood sugar after the meal lower by 20.2 mg/dL at one hour and 11.46 mg/dL at two hours |
A 90-Day Trial of an Alcoholic Extract in India
This randomized, double-blind, placebo-controlled trial enrolled 60 people aged 35 to 60 at a hospital in Bangalore. All had newly detected type 2 diabetes that required only changes in diet or lifestyle, not medication. They were randomly assigned to a placebo or to 1 g of an alcoholic extract of ivy gourd for 90 days. Everyone in both groups received standard advice on diet and physical activity for blood sugar control, and measurements were taken at the start, at day 45 and at day 90 (PMID 18000183).
The trial found a significant decrease in fasting glucose, in glucose after meals and in HbA1c in the ivy gourd group compared with the placebo group. At day 90, fasting glucose in the ivy gourd group had fallen by 16% and after-meal glucose by 18%. The abstract does not give the size of the HbA1c change.
Null result: the trial found no significant changes in blood lipid levels (cholesterol and other blood fats).
The authors concluded that the extract has “a potential hypoglycemic action in patients with mild diabetes” and that further studies are needed to explain how it works.
A Three-Month Trial of a 500 mg Herbal Preparation in Sri Lanka
This randomized, double-blind, placebo-controlled trial is indexed in PubMed as a phase II clinical trial. It recruited 158 patients with newly diagnosed type 2 diabetes (age given as 45 ± 15 years) from a university medical clinic in Galle. Seventy-nine received 500 mg of a newly developed ivy gourd herbal preparation once a day and 79 received a placebo, for three months. Of the 158, 145 completed the trial (PMID 33352495). The abstract does not say whether participants were also taking a glucose-lowering medicine.
The table gives the mean change from the start to the end of the trial in each group, exactly as the abstract reports it. The figure in brackets is the standard deviation, a measure of how much individual results varied. For every measure in the table the difference between the groups was statistically significant (p < 0.001).
| Measure | Ivy gourd group | Placebo group |
|---|---|---|
| HbA1c (percent) | 0.65 (0.54) | 0.08 (0.66) |
| Fasting plasma glucose | 1.51 (0.49) | 0.05 (0.50) |
| Fructosamine (a shorter-term marker of average glucose) | 0.02 (0.03) | −0.01 (0.04) |
| Insulin | 1.91 (3.07) | −1.28 (9.77) |
| Homeostatic model assessment for insulin resistance (HOMA-IR), a score calculated from fasting glucose and fasting insulin | 1.73 (1.36) | −0.37 (3.38) |
| Triglycerides (a blood fat) | 0.16 (0.18) | −0.04 (0.42) |
| Very-low-density lipoprotein cholesterol | 0.07 (0.08) | −0.02 (0.19) |
The abstract prints these changes as plain numbers. It does not give the units for fasting glucose, insulin or the blood fats, and it does not spell out the direction of each change; it summarizes them as a significant improvement in glycemic measures and in selected blood lipid measures. The figures are reproduced here as printed rather than converted into a statement such as “fell by”.
Null result: the abstract states that the preparation “was unable to change other outcome variables significantly when compared to the placebo” (p > 0.05). The trial’s safety measurements are reported under Safety Findings and Interactions.
A Single Meal With Leaves in Healthy Volunteers
This study, indexed in PubMed as a phase I clinical trial and described by its authors as double-blind, was done in Sri Lanka in August 2009. All participants ate the same dinner and then fasted for 10 hours. For breakfast, 61 healthy volunteers ate a meal containing 20 g of ivy gourd leaves mixed with scraped coconut and table salt. Another 61 ate a placebo meal of scraped coconut and salt. A glucose tolerance test, in which blood sugar is measured before and at set times after eating, was then carried out without the testers knowing which meal each person had eaten (PMID 21822423). The abstract does not say how people were assigned to the two groups.
Blood sugar overall was significantly lower in the leaf group (P < 0.05). The rise in blood sugar from fasting to one hour and to two hours was larger in the placebo group. The difference between the groups in blood sugar after the meal was 20.2 mg/dL at one hour (95% confidence interval 4.81 to 35.5) and 11.46 mg/dL at two hours (95% confidence interval 1.03 to 21.9). A confidence interval is the range in which the true difference is likely to lie; both ranges here are wide.
The participants were healthy, not diabetic, and the study measured one meal on one morning. The authors concluded that ivy gourd has a blood sugar lowering effect and that “further studies are needed to validate our findings”.
What the Trials Did Not Test
- No trial compared ivy gourd with metformin, a sulfonylurea, insulin or any other diabetes medicine.
- No trial added ivy gourd to existing diabetes medication. The 2008 trial enrolled only people managed by diet and lifestyle (PMID 18000183).
- No trial ran longer than about three months, so none measured long-term results such as eye, kidney or nerve complications.
- No trial included people with type 1 diabetes.
What the Reviews Concluded
Five review articles that cover ivy gourd are summarized here in date order. A review reads and weighs the published studies; it does not produce new trial data. Their conclusions are mixed, and the cautious ones are reported as they stand.
- 2003 systematic review. The reviewers searched the literature up to May 2002 and analyzed 108 trials of 36 herbs and 9 vitamin or mineral supplements, involving 4,565 patients with diabetes or impaired glucose tolerance. They concluded that there was “still insufficient evidence to draw definitive conclusions about the efficacy of individual herbs and supplements for diabetes”. Within that limit, they wrote that the best evidence for efficacy from adequately designed randomized controlled trials was available for ivy gourd (as Coccinia indica) and American ginseng (PMID 12663610). This review was published before both of the randomized trials described above.
- 2008 review of nine botanicals. The authors discussed nine plants often promoted for blood glucose, ivy gourd among them, with the emphasis on studies in people. They found a paucity of data on efficacy and safety and concluded that, because of “the lack of sufficient evidence from clinical studies for any of the botanicals reviewed, it is premature to actively recommend use of any particular herb” to treat glucose or other risk factors (PMID 18537692).
- 2014 review of five complementary medicines. The reviewers reported that clinical trials of cinnamon, bitter gourd, fenugreek and ivy gourd “showed conflicting results”. They wrote that studies were hard to compare because participants differed at the start, preparations differed, end points varied and trial design was poor, and that short study length and small numbers of participants were universal (PMID 25331834).
- 2017 review of herbal products for type 2 diabetes. The authors described the data on botanicals as conflicting and stated that large, well-designed clinical studies need to be carried out before the use of such preparations can be recommended for treating or preventing diabetes (PMID 28729836).
- 2025 review of the plant. The most recent review is the most favorable. It states that clinical trials of ivy gourd “demonstrate promising effects in managing glucose dysregulation”, while also stating that the active compounds and their mechanisms are not yet fully identified (PMID 41504092).
Read together: the 2003 review placed ivy gourd’s trial evidence among the best then available and the 2025 review calls the trials promising, while four of the five reviews state that the human evidence for botanicals of this kind is insufficient or conflicting.
What Animal and Laboratory Studies Found
Everything in this section was found in rats or in laboratory tests on enzymes and cells, not in people. Such studies show what a plant extract can do under controlled conditions and suggest how it might act. They do not show that the same thing happens in a person who eats the plant or swallows an extract.
Studies in Rats
Fruit extract in diabetic rats. Researchers made rats diabetic with streptozotocin, a chemical that damages the insulin-making cells of the pancreas, given with nicotinamide. The rats then received a chloroform extract of ivy gourd fruit by mouth at 250 mg per kilogram of body weight every day for a week. On the seventh day their fasting blood glucose was significantly lower than that of untreated diabetic rats (P < 0.05), and seven days of the extract also flattened the blood glucose curve in an oral glucose tolerance test (PMID 28479735). The authors concluded that including the fruit in food could be useful for newly diagnosed diabetic patients; that conclusion rests on a one-week rat experiment, not on a trial in people.
Leaf extract combined with a second plant, in diabetic rats. Male rats made diabetic with streptozotocin (65 mg/kg) and nicotinamide (110 mg/kg) were treated for 28 days with an ethanol extract of ivy gourd leaves (300 mg/kg), an extract of a second plant, Blumea balsamifera (150 mg/kg), mixtures of the two in ratios of 1:1, 1:3 and 3:1, or the sulfonylurea drug glibenclamide (4.5 mg/kg). Among the extracts, the 1:3 mixture lowered glucose the most. In the pancreas and liver, that mixture also lowered malondialdehyde, a marker of oxidative damage, and raised two antioxidant enzymes. Under the microscope the insulin-making islets of the pancreas showed regeneration, and the amount of insulin detected in the pancreas rose (PMID 39079440). The abstract highlights the mixture and does not report a separate result for ivy gourd leaf on its own, so this study cannot be read as a finding about ivy gourd alone.
Leaf extract and organ damage in rats. In rats given monosodium glutamate to produce liver and heart damage, an ethanol extract of ivy gourd leaves reduced the abnormal blood fats, the markers of cell damage and the inflammation that the treatment caused (PMID 33887972). This rat study concerned liver and heart protection; its abstract reports no blood sugar measurement.
Laboratory Tests on Enzymes and Cells
Leaf extract against two starch-digesting enzymes. In a laboratory study that combined computer modelling with enzyme tests, an ivy gourd leaf extract blocked alpha-amylase and alpha-glucosidase. The blocking grew stronger as the concentration rose across the range tested (7.8 to 125.0 micrograms per millilitre) and was reported as higher than that of acarbose. In cell and membrane tests over the same range, the extract showed low toxicity (PMID 39045303).
A stem compound against alpha-amylase. The compound 2,4-ditertiary butyl phenol, isolated from ivy gourd stems, blocked alpha-amylase in a laboratory test in a concentration-dependent way. Its half-maximal inhibitory concentration (IC50), the concentration that cuts the enzyme’s activity by half, was 64.36 micrograms per millilitre. Computer modelling predicted that the compound binds to human pancreatic alpha-amylase (PMID 38718496).
Two screens in which ivy gourd was not a leading performer. A study of 126 extracts from 17 Indian medicinal plants, ivy gourd included, tested each against alpha-amylase taken from pig pancreas. Strong blocking (over 50%) was found in only three extracts, from flax seed, mulberry leaf and holy basil. Ivy gourd was not one of the three, and the abstract gives no figure for it (PMID 21251279). A study of ethanol extracts from seven Thai medicinal plants, again including ivy gourd, found the strongest alpha-glucosidase blocking in mulberry and Gynostemma pentaphyllum and the highest glucose use by insulin-resistant liver cells with ginger and roselle. Ivy gourd was not named among the top results in either test (PMID 39458809).
Taken together, the laboratory record is mixed: one study found strong enzyme blocking by an ivy gourd leaf extract, and two multi-plant screens found other plants stronger.
Amounts Used in the Trials
The amounts below are what the researchers gave in each study. They are reported as facts about those studies, not as amounts for any reader to take. The preparations differed from study to study (fresh leaves, an alcoholic extract, a formulated herbal product), so the figures cannot be converted into one another.
| Study | Preparation | Amount and schedule | Length |
|---|---|---|---|
| Randomized trial in people, India, 2008 | Alcoholic extract (plant part not stated in the abstract) | 1 g | 90 days |
| Randomized trial in people, Sri Lanka, 2021 | A newly developed herbal preparation | 500 mg once daily | Three months |
| Single-meal study in healthy volunteers, Sri Lanka, 2011 | Leaves mixed with scraped coconut and salt | 20 g of leaves in one breakfast | One meal |
| Rat study, 2017 | Chloroform extract of the fruit | 250 mg per kilogram of body weight daily | One week |
| Rat study, 2024 | Ethanol extract of the leaves, alone and mixed with a second plant | 300 mg per kilogram of body weight | 28 days |
Sources: PMID 18000183, PMID 33352495, PMID 21822423, PMID 28479735, PMID 39079440.
The abstract of the 2008 trial gives the amount as “1 g alcoholic extract of the herb for 90 days” and does not say how the amount was divided across the day. Amounts given to rats are scaled to the animal’s body weight and do not translate directly into an amount for a person.
Safety Findings and Interactions
What the Trials Recorded
In the three-month Sri Lankan trial, blood pressure, blood counts and the kidney and liver test results were checked every two weeks. All stayed within normal reference ranges at each visit, and the authors described the 500 mg daily preparation as well tolerated (PMID 33352495). The abstracts of the 2008 Indian trial and the 2011 single-meal study report no safety findings, good or bad (PMID 18000183, PMID 21822423).
Across all the herbs and supplements it covered, the 2003 systematic review found that very few adverse effects were reported and that the products “appear to be generally safe” (PMID 12663610). The 2008 review, by contrast, described a paucity of safety data for these botanicals in human studies (PMID 18537692), and the 2014 review called for well-designed long-term trials of their adverse effects (PMID 25331834). Few reported harms in short, small trials is not the same as proven long-term safety.
Liver Toxicity at High Doses
The 2025 review reports that toxicological evaluations indicate ivy gourd is generally safe, but that high doses can cause dose-dependent hepatotoxicity, meaning liver damage that grows with the dose (PMID 41504092). The abstract does not give the dose at which this was seen, and it does not say whether the evaluations were done in animals or in people.
Two other records touch the liver. In the three-month human trial, liver test results stayed in the normal range at 500 mg a day (PMID 33352495). In a rat study, a leaf extract reduced chemically induced liver damage (PMID 33887972). Neither finding cancels the review’s statement about high doses; a substance can be harmless or even protective at one dose and damaging at a much higher one.
Low Blood Sugar When Combined With Diabetes Medicines
None of the studies behind this page tested ivy gourd together with insulin or diabetes tablets, so the size of any combined effect has not been measured. The general fact applies: anything that lowers blood sugar adds to the effect of insulin and of sulfonylurea drugs, and the combined effect can be low blood sugar (hypoglycemia). The papers themselves describe ivy gourd as a “hypoglycemic agent”, that is, something that lowers blood sugar (PMID 21822423).
Signs of low blood sugar are shakiness, sweating, a fast heartbeat and confusion, and at lower levels seizure or loss of consciousness. The page on hypoglycemia awareness and prevention describes them in detail.
No study in this record examined whether ivy gourd changes how the body absorbs or breaks down other medicines. That question is unstudied here, not answered.
Type 1 Diabetes
Type 1 diabetes is a state of absolute insulin deficiency. No herb, food or diet replaces insulin; without insulin, diabetic ketoacidosis develops, and it is fatal if untreated. Every human study of ivy gourd described on this page was done in people with type 2 diabetes or in healthy volunteers.
Pregnancy, Breastfeeding, Children and Long-Term Use
None of the records behind this page reports data on ivy gourd extracts in pregnancy, during breastfeeding or in children. The 2008 trial enrolled people aged 35 to 60, and the 2021 trial gives its participants’ age as 45 ± 15 years. The longest trial lasted about three months, so there are no trial data on use for longer than that. These gaps concern extracts and formulated products; the 2025 review describes the plant itself as a regular vegetable in South Asia (PMID 41504092).
Differences From One Product to the Next
Herbal products vary in plant part, extract and content from one product to the next, so a trial result for one preparation does not transfer to another. For ivy gourd this is a practical problem. The two diabetes trials used two different preparations, the abstracts do not state which part of the plant either one was made from, and neither abstract names a measured active compound. The 2014 review named differences in preparation as one reason the trials are hard to compare (PMID 25331834).
Computer Toxicity Predictions for One Compound
For the stem compound 2,4-ditertiary butyl phenol, computer prediction tools flagged skin irritation and predicted no cancer-causing, gene-damaging or liver-damaging effect (PMID 38718496). These are software predictions for a single isolated compound, not observations in animals or people.
Limits of the Evidence
The human evidence for ivy gourd is thin, and that is itself a finding worth knowing.
- Two trials in people with diabetes. One enrolled 60 people and the other 158. Each lasted about three months. Each was done at a single site, one in India and one in Sri Lanka (PMID 18000183, PMID 33352495).
- Early, mild diabetes only. Both trials studied newly diagnosed type 2 diabetes; the 2008 authors themselves describe their finding as applying to “patients with mild diabetes”. The results say nothing about long-standing diabetes or diabetes already treated with medication.
- Placebo comparisons only. No trial measured ivy gourd against a diabetes drug, so there is no basis in this record for saying it works as well as, or in place of, any medicine.
- Different preparations. A 1 g alcoholic extract and a 500 mg formulated product are not the same thing, and neither is the same as leaves in a meal. Each result belongs to the preparation that was tested.
- Blood test results, not health outcomes. The trials measured glucose, HbA1c and related blood tests over three months. None measured heart disease, kidney disease, eye disease, nerve damage or survival.
- Healthy volunteers and one meal. The leaf-meal study shows a smaller blood sugar rise after one breakfast in healthy people. It does not show what daily leaves do in diabetes (PMID 21822423).
- The active compound is unknown. The 2025 review states that the compounds behind the effects and their mechanisms are yet to be fully identified (PMID 41504092). The enzyme-blocking and insulin findings come from laboratory tests and rats.
- Reviewers’ own judgement. Reviews from 2003, 2008, 2014 and 2017 describe the evidence for blood sugar botanicals, ivy gourd included, as insufficient, conflicting or in need of large, well-designed trials (PMID 12663610, PMID 18537692, PMID 25331834, PMID 28729836).
- Abstracts only. This page reports what each paper’s PubMed abstract states. Details that an abstract leaves out, such as the plant part in a formulation or the units of a measurement, are marked as not stated rather than filled in.
Key Research Papers
- Kuriyan R, Rajendran R, Bantwal G, Kurpad AV. Effect of supplementation of Coccinia cordifolia extract on newly detected diabetic patients. Diabetes Care. 2008;31(2):216-20. PubMed PMID: 18000183
- Wasana KGP, Attanayake AP, Weerarathna TP, Jayatilaka KAPW. Efficacy and safety of a herbal drug of Coccinia grandis (Linn.) Voigt in patients with type 2 diabetes mellitus: A double blind randomized placebo controlled clinical trial. Phytomedicine. 2021;81:153431. PubMed PMID: 33352495
- Munasinghe MA, Abeysena C, Yaddehige IS, Vidanapathirana T, Piyumal KP. Blood sugar lowering effect of Coccinia grandis (L.) J. Voigt: path for a new drug for diabetes mellitus. Exp Diabetes Res. 2011;2011:978762. PubMed PMID: 21822423
- Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277-94. PubMed PMID: 12663610
- Cefalu WT, Ye J, Wang ZQ. Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets. 2008;8(2):78-81. PubMed PMID: 18537692
- Medagama AB, Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? Nutr J. 2014;13:102. PubMed PMID: 25331834
- Ota A, Ulrih NP. An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes. Front Pharmacol. 2017;8:436. PubMed PMID: 28729836
- Siam NH, Snigdha NN. Ethnomedicinal Uses, Phytochemistry, Pharmacological Activity, Therapeutic Potentials, and Functional Foods of Coccinia grandis (L.) Voigt: An Updated Review. Front Biosci (Elite Ed). 2025;17(4):37698. PubMed PMID: 41504092
- Rahmatullah M, Azam MN, Khatun Z, Seraj S, Islam F, Rahman MA, et al. Medicinal plants used for treatment of diabetes by the Marakh sect of the Garo tribe living in Mymensingh district, Bangladesh. Afr J Tradit Complement Altern Med. 2012;9(3):380-5. PubMed PMID: 23983370
- Kaushik U, Aeri V, Showkat RM, Ali M. Cucurbitane-Type Triterpenoids from the Blood Glucose-Lowering Extracts of Coccinia indica and Momordica balsamina Fruits. Pharmacogn Mag. 2017;13(Suppl 1):S115-S121. PubMed PMID: 28479735
- Putra IMWA, Fakhrudin N, Nurrochmad A, Wahyuono S. Antidiabetic effect of combined extract of Coccinia grandis and Blumea balsamifera on streptozotocin-nicotinamide induced diabetic rats. J Ayurveda Integr Med. 2024;15(4):101021. PubMed PMID: 39079440
- Banerjee A, Mukherjee S, Maji BK. Efficacy of Coccinia grandis against monosodium glutamate induced hepato-cardiac anomalies by inhibiting NF-kB and caspase 3 mediated signalling in rat model. Hum Exp Toxicol. 2021;40(11):1825-1851. PubMed PMID: 33887972
- Prabhakar P, Mukherjee S, Kumar A, Rout RK, Kumar S, Verma DK, et al. In Silico, In Vitro and Ex Vivo Evaluation of the Antihyperglycaemic, Antioxidant and Cytotoxic Properties of Coccinia grandis L. Leaf Extract. Food Technol Biotechnol. 2024;62(2):188-204. PubMed PMID: 39045303
- Momin YH, Yeligar VC, Saralaya MG, Dharmamoorthy G, Mallikarjuna BP, Jadhav ST, et al. Computational investigation of 2, 4-Di Tert Butyl Phenol as alpha amylase inhibitor isolated from Coccinia grandis (L.) Voigt using molecular docking, and ADMET parameters. Comput Biol Chem. 2024;110:108087. PubMed PMID: 38718496
- P S, Zinjarde SS, Bhargava SY, Kumar AR. Potent α-amylase inhibitory activity of Indian Ayurvedic medicinal plants. BMC Complement Altern Med. 2011;11:5. PubMed PMID: 21251279
- Bunyakitcharoen A, Taychaworaditsakul W, Sireeratawong S, Chansakaow S. Anti-Hyperglycemic Effects of Thai Herbal Medicines. Plants (Basel). 2024;13(20):2862. PubMed PMID: 39458809
PubMed Topic Searches
Connections
- Diabetes — the section home
- Natural Remedies for Blood Sugar — the full index
- Type 2 Diabetes
- Insulin Resistance
- How Herbs Lower Blood Sugar — the five ways a plant can act
- Bitter Melon — another gourd-family plant studied for blood sugar
- American Ginseng for Blood Sugar — named beside ivy gourd in the 2003 systematic review
- Gymnema
- Fenugreek
- Hemoglobin A1C — the three-month blood sugar test
- Hypoglycemia Awareness and Prevention — the signs of low blood sugar
- Glucose Monitoring